Fabio Massari

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bente Langdahl, Cesar Libanati, Daria B. Crittenden et al. · The Lancet · 2017 · 467 citations

Medicine, Endocrinology, Pharmacotherapy +14

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Jacques P. Brown, Klaus Engelke, Tony M. Keaveny et al. · Journal of Bone and Mineral Research · 2021 · 73 citations · Full text

Medicine, Orthopedic Surgery, Bone Augmentation +16

Impaired Bone Microarchitecture Improves After One Year On Gluten-Free Diet: A Prospective Longitudinal HRpQCT Study in Women With Celiac Disease

María Belén Zanchetta, Vanesa Longobardi, Florencia Costa et al. · Journal of Bone and Mineral Research · 2016 · 52 citations · Full text

Medicine, Nutrition, Nutritional Sciences +17

Fenofibrate or Gemfibrozil for Treatment of Types IIa and IIb Primary Hyperlipoproteinemia: A Randomized, Double-Blind, Crossover Study

Fabio Massari, Juan José Rodríguez Moncalvo, José Zanchetta et al. · Endocrine Practice · 2002 · 36 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Postmenopausal women with sarcopenia have higher prevalence of falls and vertebral fractures.

María Belén Zanchetta, Rubén Abdala, Fabio Massari et al. · PubMed · 2021 · 13 citations · Full text

Medicine, Geriatric Medicine, Bone Metabolism +16